TABLE 3.
Efficacy of Debio-025 against various HIV-1 subtype isolates in PBMCsa
| Virus | Subtype | Coreceptor usageb | IC50 (μM)c |
|---|---|---|---|
| 92RW016 | A | R5 | 0.008 ± 0.003 |
| 92UG037 | A | R5 | 0.016 ± 0.012 |
| NL4-3 | B | X4 | 0.010 ± 0.007 |
| JR-CSF | B | R5 | 0.015 ± 0.009 |
| SF162 | B | R5 | 0.015 ± 0.005 |
| Ba-L | B | R5 | 3.53 ± 1.74 |
| 92BR014 | B | R5X4 | 5.65 ± 2.43 |
| SLKA | Bd | R5 | 0.025e |
| TEKI | Bd | R5 | 4.41 ± 3.12 |
| ROJO | Bd | X4 | 0.024 ± 0.022 |
| WEJO | Bd | X4 | 0.015 ± 0.006 |
| 92BR025 | C | R5 | 0.015 ± 0.009 |
| 92UG046 | D | X4 | 0.010 ± 0.005 |
| CMU02 | EA | X4 | 5.66 ± 0.42 |
| 93BR020 | F | R5X4 | 5.53 ± 2.69 |
| Jv1083 | G | R5 | 6.25 ± 0.34 |
| BCF01 | O | R5 | 6.25 ± 0.98 |
a
Efficacy was measured as RT activity.
b
R5, CCR5; X4, CXCR4; R5X4, CCR5/CXCR4 dual tropic.
c
Values are means ± standard deviations from 2 to 12 independent assays, depending on the virus isolate.
d
Presumed subtype B.
e
The value for HIV-1 SLKA is from a single assay.